Drugs /

durvalumab

Back to Drugs List
Associated Genetic Biomarkers

Overview

Generic Name(s):
durvalumab
Trade Name(s):
Imfinzi
NCI Definition [1]:
A monoclonal antibody directed against B7H1 (B7 homolog 1; programmed cell death ligand 1) with potential immunostimulating activity. Upon intravenous administration, durvalumab binds to the cell surface antigen B7H1, thereby blocking B7H1 signaling. This may activate the immune system to exert a cytotoxic T-lymphocyte (CTL) response against B7H1-expressing tumor cells. B7H1, a member of the B7 protein superfamily and a negative regulator of cytokine synthesis, is overexpressed on certain tumor cell types.

Clinical Trials

View Clinical Trials for durvalumab

Durvalumab has been investigated in 282 clinical trials, of which 251 are open and 31 are closed. Of the trials investigating durvalumab, 5 are early phase 1 (4 open), 54 are phase 1 (46 open), 54 are phase 1/phase 2 (52 open), 135 are phase 2 (116 open), 1 is phase 2/phase 3 (0 open), 30 are phase 3 (30 open), 1 is phase 4 (1 open), and 2 are no phase specified (2 open).

HER2 Deficient Expression, HER2 Negative, and EGFR Exon 19 Deletion are the most frequent biomarker inclusion criteria for durvalumab clinical trials.

Non-small cell lung carcinoma, breast carcinoma, and malignant solid tumor are the most common diseases being investigated in durvalumab clinical trials [2].

Top Biomarker Inclusion Criteria for Open Clinical Trials Investigating Durvalumab
Top Biomarker Inclusion Criteria for Closed Clinical Trials Investigating Durvalumab
This graph displays the 20 most frequently occurring biomarkers curated on clinical trials investigating durvalumab and the cancer types associated with these biomarkers. These numbers are derived from a set of 5,956 clinical trials for which biomarker status defines treatment.

Drug Details

Synonyms [2]:
medi4736, Imfinzi, durvalumab, medi-4736, immunoglobulin g1, anti-(human protein b7-h1) (human monoclonal medi4736 heavy chain), disulfide with human monoclonal medi4736 kappa-chain, dimer, immunoglobulin g1, anti-(human protein b7-h1) (human monoclonal medi4736 heavy chain), disulfide with human monoclonal medi4736 kappa-chain, dimer
Drug Categories [2]:
Anti-PD-L1 antibodies, Immunotherapies, Therapeutic antibodies
Drug Target(s) [2]:
CD274
NCIT ID [1]:
C103194

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.